oxymorphone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
opioid receptor antagonists/agonists, morphinan derivates	2034	76-41-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: oxymorphone 14-Hydroxydihydromorphinone (-)-Oxymorphone oxymorphone hydrochloride oxymorphone HCl	An opioid analgesic with actions and uses similar to those of MORPHINE, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092) Molecular weight: 301.34 Formula: C17H19NO4 CLOGP: -0.48 LIPINSKI: 0 HAC: 5 HDO: 2 TPSA: 70 ALOGS: -1.07 ROTB: 0 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

oxymorphone
14-Hydroxydihydromorphinone
(-)-Oxymorphone
oxymorphone hydrochloride
oxymorphone HCl

An opioid analgesic with actions and uses similar to those of MORPHINE, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092)

Molecular weight: 301.34
Formula: C17H19NO4
CLOGP: -0.48
LIPINSKI: 0
HAC: 5
HDO: 2
TPSA: 70
ALOGS: -1.07
ROTB: 0

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	24 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	1.90 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.43 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	10 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
April 2, 1959	FDA	ENDO PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Toxicity to various agents	227.62	27.65	137	2576	247113	63239196
Drug abuse	224.52	27.65	92	2621	72426	63413883
Completed suicide	188.35	27.65	101	2612	145572	63340737
Drug use disorder	113.87	27.65	29	2684	4955	63481354
Intentional product misuse	94.88	27.65	48	2665	60869	63425440
Respiratory arrest	69.82	27.65	32	2681	32613	63453696
Injection site abscess	64.64	27.65	14	2699	1184	63485125
Cardio-respiratory arrest	61.91	27.65	36	2677	59923	63426386
Staphylococcal bacteraemia	55.98	27.65	17	2696	5513	63480796
Accidental poisoning	55.22	27.65	11	2702	617	63485692
Death	52.89	27.65	72	2641	374309	63112000
Cardiac arrest	47.66	27.65	36	2677	92509	63393800
Injection site cellulitis	47.64	27.65	11	2702	1243	63485066
Intentional product use issue	47.32	27.65	41	2672	127851	63358458
Endocarditis	46.96	27.65	15	2698	5735	63480574
Fanconi syndrome	41.32	27.65	10	2703	1382	63484927
Accidental death	37.85	27.65	10	2703	1966	63484343
Overdose	34.89	27.65	33	2680	115045	63371264
Drug dependence	31.49	27.65	17	2696	24466	63461843
Drug screen positive	27.72	27.65	9	2704	3620	63482689

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug abuse	285.18	37.27	130	1896	98966	34855939
Toxicity to various agents	209.14	37.27	134	1892	200228	34754677
Drug use disorder	124.68	37.27	32	1994	4159	34950746
Drug dependence	102.56	37.27	42	1984	24175	34930730
Completed suicide	97.44	37.27	64	1962	98104	34856801
Intentional product misuse	94.31	37.27	48	1978	45563	34909342
Accidental overdose	75.36	37.27	32	1994	20108	34934797
Drug withdrawal syndrome	72.51	37.27	31	1995	19803	34935102
Injection site abscess	70.90	37.27	15	2011	834	34954071
Intentional product use issue	66.60	37.27	42	1984	59774	34895131
Injection site cellulitis	58.58	37.27	12	2014	569	34954336
Endocarditis	48.18	37.27	17	2009	6494	34948411
Overdose	40.58	37.27	37	1989	91022	34863883
Therapeutic product effect decreased	37.61	37.27	24	2002	34719	34920186
Pneumomediastinum	37.39	37.27	11	2015	2356	34952549

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug abuse	471.87	27.33	204	3675	162487	79578022
Toxicity to various agents	433.72	27.33	262	3617	421278	79319231
Completed suicide	280.46	27.33	164	3715	245603	79494906
Drug use disorder	238.48	27.33	60	3819	8591	79731918
Intentional product misuse	185.64	27.33	91	3788	95074	79645435
Injection site abscess	142.17	27.33	29	3850	1611	79738898
Intentional product use issue	113.76	27.33	78	3801	152034	79588475
Injection site cellulitis	106.90	27.33	23	3856	1655	79738854
Endocarditis	100.75	27.33	32	3847	10565	79729944
Respiratory arrest	100.12	27.33	51	3828	57499	79683010
Staphylococcal bacteraemia	96.28	27.33	32	3847	12186	79728323
Cardio-respiratory arrest	91.51	27.33	60	3819	108450	79632059
Accidental overdose	89.60	27.33	42	3837	39539	79700970
Death	86.72	27.33	121	3758	566393	79174116
Drug dependence	76.36	27.33	38	3841	40731	79699778
Cardiac arrest	62.96	27.33	58	3821	172038	79568471
Accidental death	62.48	27.33	18	3861	4273	79736236
Staphylococcal infection	53.42	27.33	34	3845	58261	79682248
Drug withdrawal syndrome	52.41	27.33	28	3851	34690	79705819
Overdose	48.64	27.33	52	3827	184154	79556355
Accidental poisoning	43.17	27.33	11	3868	1646	79738863
Acute kidney injury	41.42	27.33	83	3796	519321	79221188
Drug screen positive	40.36	27.33	14	3865	6049	79734460
Thrombotic microangiopathy	38.33	27.33	19	3860	20150	79720359
Pneumomediastinum	34.53	27.33	11	3868	3656	79736853
Substance abuse	29.58	27.33	13	3866	10513	79729996
Oesophageal rupture	28.28	27.33	7	3872	932	79739577

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N02AA11	NERVOUS SYSTEM ANALGESICS OPIOIDS Natural opium alkaloids
MeSH PA	D000759	Adjuvants, Anesthesia
MeSH PA	D000700	Analgesics
MeSH PA	D000701	Analgesics, Opioid
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D009294	Narcotics
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D018689	Sensory System Agents
FDA MoA	N0000175684	Full Opioid Agonists
FDA EPC	N0000175690	Opioid Agonist

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Pain	indication	22253000
General anesthesia	indication	50697003
Severe pain	indication	76948002
Chronic pain	indication	82423001
Labor pain	indication	247412007
Local anesthesia	indication	386761002
Severe Pain with Opioid Tolerance	indication
Chronic Pain with Opioid Tolerance	indication
Anxiety due to Cardiac Asthma	indication
Suicidal thoughts	contraindication	6471006
Dependent drug abuse	contraindication	6525002
Alcohol withdrawal delirium	contraindication	8635005
Asthenia	contraindication	13791008
Constipation	contraindication	14760008	DOID:2089
Mood swings	contraindication	18963009
Inflammatory bowel disease	contraindication	24526004	DOID:0050589
Alcohol intoxication	contraindication	25702006
Shock	contraindication	27942005
Hypercapnia	contraindication	29596007
Dehydration	contraindication	34095006
Disorder of gallbladder	contraindication	39621005	DOID:0060262
Hypothyroidism	contraindication	40930008	DOID:1459
Conduction disorder of the heart	contraindication	44808001
Low blood pressure	contraindication	45007003
Bradycardia	contraindication	48867003
Ulcerative colitis	contraindication	64766004	DOID:8577
Substance abuse	contraindication	66214007
Benign intracranial hypertension	contraindication	68267002	DOID:11459
Urethral stricture	contraindication	76618002
Decreased respiratory function	contraindication	80954004
Injury of head	contraindication	82271004
Cor pulmonale	contraindication	83291003	DOID:8515
Pulmonary emphysema	contraindication	87433001
Kidney disease	contraindication	90708001	DOID:557
Acute abdominal pain	contraindication	116290004
Neoplasm of brain	contraindication	126952004	DOID:1319
Seizure disorder	contraindication	128613002
Drug-induced psychosis	contraindication	191483003	DOID:1742
Disease of liver	contraindication	235856003	DOID:409
Morbid obesity	contraindication	238136002	DOID:11981
Benign prostatic hyperplasia	contraindication	266569009
Retention of urine	contraindication	267064002
Exacerbation of asthma	contraindication	281239006
Lesion of brain	contraindication	301766008
Coma	contraindication	371632003
Primary adrenocortical insufficiency	contraindication	373662000
Operation on gastrointestinal tract	contraindication	386621005
Hypoxia	contraindication	389086002
Central nervous system depression	contraindication	418072004
Dysfunction of sphincter of Oddi	contraindication	430887001

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.31	acidic
pKa2	7.97	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
10MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	OPANA ER	ENDO PHARMS	N021610	June 22, 2006	DISCN	TABLET, EXTENDED RELEASE	ORAL	7276250	Feb. 4, 2023	RELIEF OF MODERATE TO SEVERE PAIN
15MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	OPANA ER	ENDO PHARMS	N021610	Feb. 29, 2008	DISCN	TABLET, EXTENDED RELEASE	ORAL	7276250	Feb. 4, 2023	RELIEF OF MODERATE TO SEVERE PAIN
20MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	OPANA ER	ENDO PHARMS	N021610	June 22, 2006	DISCN	TABLET, EXTENDED RELEASE	ORAL	7276250	Feb. 4, 2023	RELIEF OF MODERATE TO SEVERE PAIN
30MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	OPANA ER	ENDO PHARMS	N021610	Feb. 29, 2008	DISCN	TABLET, EXTENDED RELEASE	ORAL	7276250	Feb. 4, 2023	RELIEF OF MODERATE TO SEVERE PAIN
40MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	OPANA ER	ENDO PHARMS	N021610	June 22, 2006	DISCN	TABLET, EXTENDED RELEASE	ORAL	7276250	Feb. 4, 2023	RELIEF OF MODERATE TO SEVERE PAIN
5MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	OPANA ER	ENDO PHARMS	N021610	June 22, 2006	DISCN	TABLET, EXTENDED RELEASE	ORAL	7276250	Feb. 4, 2023	RELIEF OF MODERATE TO SEVERE PAIN
7.5MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	OPANA ER	ENDO PHARMS	N021610	Feb. 29, 2008	DISCN	TABLET, EXTENDED RELEASE	ORAL	7276250	Feb. 4, 2023	RELIEF OF MODERATE TO SEVERE PAIN
10MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	OPANA ER	ENDO PHARMS	N021610	June 22, 2006	DISCN	TABLET, EXTENDED RELEASE	ORAL	8808737	June 21, 2027	DOSE MODIFICATION FOR RENAL IMPAIRMENT
15MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	OPANA ER	ENDO PHARMS	N021610	Feb. 29, 2008	DISCN	TABLET, EXTENDED RELEASE	ORAL	8808737	June 21, 2027	DOSE MODIFICATION FOR RENAL IMPAIRMENT
20MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	OPANA ER	ENDO PHARMS	N021610	June 22, 2006	DISCN	TABLET, EXTENDED RELEASE	ORAL	8808737	June 21, 2027	DOSE MODIFICATION FOR RENAL IMPAIRMENT
30MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	OPANA ER	ENDO PHARMS	N021610	Feb. 29, 2008	DISCN	TABLET, EXTENDED RELEASE	ORAL	8808737	June 21, 2027	DOSE MODIFICATION FOR RENAL IMPAIRMENT
40MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	OPANA ER	ENDO PHARMS	N021610	June 22, 2006	DISCN	TABLET, EXTENDED RELEASE	ORAL	8808737	June 21, 2027	DOSE MODIFICATION FOR RENAL IMPAIRMENT
5MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	OPANA ER	ENDO PHARMS	N021610	June 22, 2006	DISCN	TABLET, EXTENDED RELEASE	ORAL	8808737	June 21, 2027	DOSE MODIFICATION FOR RENAL IMPAIRMENT
7.5MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	OPANA ER	ENDO PHARMS	N021610	Feb. 29, 2008	DISCN	TABLET, EXTENDED RELEASE	ORAL	8808737	June 21, 2027	DOSE MODIFICATION FOR RENAL IMPAIRMENT
10MG	OPANA ER	ENDO PHARMS	N201655	Dec. 9, 2011	DISCN	TABLET, EXTENDED RELEASE	ORAL	8808737	June 21, 2027	METHOD OF ADMINISTRATION OF CONTROLLED RELEASE OXYMORPHONE
15MG	OPANA ER	ENDO PHARMS	N201655	Dec. 9, 2011	DISCN	TABLET, EXTENDED RELEASE	ORAL	8808737	June 21, 2027	METHOD OF ADMINISTRATION OF CONTROLLED RELEASE OXYMORPHONE
20MG	OPANA ER	ENDO PHARMS	N201655	Dec. 9, 2011	DISCN	TABLET, EXTENDED RELEASE	ORAL	8808737	June 21, 2027	METHOD OF ADMINISTRATION OF CONTROLLED RELEASE OXYMORPHONE
30MG	OPANA ER	ENDO PHARMS	N201655	Dec. 9, 2011	DISCN	TABLET, EXTENDED RELEASE	ORAL	8808737	June 21, 2027	METHOD OF ADMINISTRATION OF CONTROLLED RELEASE OXYMORPHONE
40MG	OPANA ER	ENDO PHARMS	N201655	Dec. 9, 2011	DISCN	TABLET, EXTENDED RELEASE	ORAL	8808737	June 21, 2027	METHOD OF ADMINISTRATION OF CONTROLLED RELEASE OXYMORPHONE
5MG	OPANA ER	ENDO PHARMS	N201655	Dec. 9, 2011	DISCN	TABLET, EXTENDED RELEASE	ORAL	8808737	June 21, 2027	METHOD OF ADMINISTRATION OF CONTROLLED RELEASE OXYMORPHONE
7.5MG	OPANA ER	ENDO PHARMS	N201655	Dec. 9, 2011	DISCN	TABLET, EXTENDED RELEASE	ORAL	8808737	June 21, 2027	METHOD OF ADMINISTRATION OF CONTROLLED RELEASE OXYMORPHONE

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Mu-type opioid receptor	GPCR	P35372	OPRM_HUMAN	AGONIST	Ki	9.44	WOMBAT-PK	CHEMBL
Kappa-type opioid receptor	GPCR	P41145	OPRK_HUMAN	AGONIST	Ki	6.83	WOMBAT-PK	CHEMBL
Delta-type opioid receptor	GPCR	P41143	OPRD_HUMAN	AGONIST	Ki	7.30	CHEMBL	CHEMBL
Mu-type opioid receptor	GPCR		OPRM_RAT		Ki	9.01	CHEMBL
Mu-type opioid receptor	GPCR		OPRM_MOUSE		Ki	8.30	CHEMBL
Mu-type opioid receptor	GPCR		OPRM_CAVPO		Ki	9.27	CHEMBL
Delta-type opioid receptor	GPCR		OPRD_MOUSE		Ki	6.21	CHEMBL
Delta-type opioid receptor	GPCR		OPRD_RAT		Ki	7.09	CHEMBL
Kappa-type opioid receptor	GPCR		OPRK_CAVPO		Ki	7.24	CHEMBL
Kappa-type opioid receptor	GPCR		OPRK_RAT		Ki	7.02	CHEMBL
Opioid receptor	GPCR		OPRD_RAT OPRM_RAT OPRK_RAT SGMR1_RAT		IC50	10.89	CHEMBL
Opioid receptors; mu and delta	GPCR		OPRD_MOUSE OPRM_MOUSE		Ki	8.33	CHEMBL

External reference:

ID	Source
4019871	VUID
N0000147956	NUI
D00844	KEGG_DRUG
357-07-3	SECONDARY_CAS_RN
4019062	VANDF
4019871	VANDF
C0030073	UMLSCUI
CHEBI:7865	CHEBI
CHEMBL963	ChEMBL_ID
DB01192	DRUGBANK_ID
CHEMBL1200794	ChEMBL_ID
D010111	MESH_DESCRIPTOR_UI
5284604	PUBCHEM_CID
7094	IUPHAR_LIGAND_ID
937	INN_ID
9VXA968E0C	UNII
7814	RXNORM
177273	MMSL
5220	MMSL
d00833	MMSL
001548	NDDF
004623	NDDF
24751001	SNOMEDCT_US
370266008	SNOMEDCT_US
69899006	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Oxymorphone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0283	TABLET	5 mg	ORAL	ANDA	33 sections
Oxymorphone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0283	TABLET	5 mg	ORAL	ANDA	33 sections
Oxymorphone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0283	TABLET	5 mg	ORAL	ANDA	33 sections
Oxymorphone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0284	TABLET	10 mg	ORAL	ANDA	33 sections
Oxymorphone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0284	TABLET	10 mg	ORAL	ANDA	33 sections
Oxymorphone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0284	TABLET	10 mg	ORAL	ANDA	33 sections
Oxymorphone hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1231	TABLET, FILM COATED, EXTENDED RELEASE	5 mg	ORAL	ANDA	32 sections
Oxymorphone hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1231	TABLET, FILM COATED, EXTENDED RELEASE	5 mg	ORAL	ANDA	32 sections
Oxymorphone hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1232	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	32 sections
Oxymorphone hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1232	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	32 sections
Oxymorphone hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1233	TABLET, FILM COATED, EXTENDED RELEASE	20 mg	ORAL	ANDA	32 sections
Oxymorphone hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1233	TABLET, FILM COATED, EXTENDED RELEASE	20 mg	ORAL	ANDA	32 sections
Oxymorphone hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1234	TABLET, FILM COATED, EXTENDED RELEASE	40 mg	ORAL	ANDA	32 sections
Oxymorphone hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1234	TABLET, FILM COATED, EXTENDED RELEASE	40 mg	ORAL	ANDA	32 sections
Oxymorphone hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1315	TABLET, FILM COATED, EXTENDED RELEASE	7.50 mg	ORAL	ANDA	32 sections
Oxymorphone hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1315	TABLET, FILM COATED, EXTENDED RELEASE	7.50 mg	ORAL	ANDA	32 sections
Oxymorphone hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1316	TABLET, FILM COATED, EXTENDED RELEASE	15 mg	ORAL	ANDA	32 sections
Oxymorphone hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1316	TABLET, FILM COATED, EXTENDED RELEASE	15 mg	ORAL	ANDA	32 sections
Oxymorphone hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1317	TABLET, FILM COATED, EXTENDED RELEASE	30 mg	ORAL	ANDA	32 sections
Oxymorphone hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1317	TABLET, FILM COATED, EXTENDED RELEASE	30 mg	ORAL	ANDA	32 sections
Oxymorphone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	10702-070	TABLET	5 mg	ORAL	ANDA	35 sections
Oxymorphone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	10702-070	TABLET	5 mg	ORAL	ANDA	35 sections
Oxymorphone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	10702-071	TABLET	10 mg	ORAL	ANDA	35 sections
Oxymorphone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	10702-071	TABLET	10 mg	ORAL	ANDA	35 sections
Oxymorphone Hydrochloride	Human Prescription Drug Label	1	13107-103	TABLET	5 mg	ORAL	ANDA	33 sections
Oxymorphone Hydrochloride	Human Prescription Drug Label	1	13107-104	TABLET	10 mg	ORAL	ANDA	33 sections
OPANAER	HUMAN PRESCRIPTION DRUG LABEL	1	16590-609	TABLET, FILM COATED, EXTENDED RELEASE	40 mg	ORAL	NDA	18 sections
OPANAER	HUMAN PRESCRIPTION DRUG LABEL	1	16590-747	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	NDA	18 sections
OPANA	HUMAN PRESCRIPTION DRUG LABEL	1	16590-765	TABLET	10 mg	ORAL	NDA	30 sections
OPANAER	HUMAN PRESCRIPTION DRUG LABEL	1	16590-767	TABLET, FILM COATED, EXTENDED RELEASE	5 mg	ORAL	NDA	18 sections